Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296385773> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- W4296385773 endingPage "S520" @default.
- W4296385773 startingPage "S519" @default.
- W4296385773 abstract "Background: Chemotherapy-induced mucositis is a common condition caused by the breakdown of the mucosal barrier. Administration of exogenous glucagon-like peptide 2 (GLP-2) has been associated with reduced epithelial damage, decreased bacterial infection, and decreased mortality or gut injury in rodents with chemically induced enteritis. GLP-2 decreases chemotherapy-induced mucositis via inhibition of drug-induced apoptosis in the small and large bowel. Apraglutide is a novel, long-acting synthetic GLP-2 agonist that has been shown to promote intestinal growth and repair. Two preclinical studies aim to evaluate the efficacy of apraglutide (3.3 mg/kg) as pre-treatment or concomitant treatment in models of chemotherapy-induced intestinal damage with cytarabine or melphalan; both extensively used in hemato-oncology. Methods: Study 1 included four groups of Balb/c mice: (A) vehicle only; (B) cytarabine on Days 5-9, no apraglutide given; (C) cytarabine on Days 5-9; concomitant apraglutide on Days 5-18; (D) cytarabine on Days 5-9; pre-treatment apraglutide on Days 1, 3, and continued as a concomitant treatment on Days 5, 8, 11, 14, and 17. Study 2 included three treatment groups of Balb/c mice: (A) vehicle only; (B) melphalan on Day 9, no apraglutide; (C) melphalan on Day 9; pre-treatment apraglutide on Days 1, 3, 5, 7 and continued as a concomitant treatment on Days 9, 11, and 13. In both models, mice that received the vehicle without any treatment served as controls. Intestinal tissue histology, body weight, survival, and plasma citrulline, a marker of total mucosal mass and intestinal growth, were assessed in both models. Results: Histological examination showed that the degenerative intestinal changes (villi and crypt atrophy) caused by cytarabine or melphalan were reduced by apraglutide co-administration, as demonstrated by similarities in tissue morphology between vehicle-treated and apraglutide-treated mice. In addition, the duodenum, ileum, and jejunum increased in weight with apraglutide. The intestinal protective effects of apraglutide were further supported by preserving plasma citrulline levels (a biomarker of intestinal mass): apraglutide-treated mice had similar levels to animals that did not receive chemotherapy. Apraglutide attenuated chemotherapy-induced weight loss and improved overall survival vs. vehicle-only or chemotherapy-only groups. The effects of apraglutide were optimal when it was administered as pre-treatment before chemotherapy. Conclusion: Microscopic examination showed apraglutide protected GI epithelium structure from chemotherapy-induced injury, improved survival, and prevented severe body weight loss in mice undergoing chemotherapy. Apraglutide also maintained plasma citrulline levels, a marker of intestinal mass, comparable mice that did not undergo chemotherapy." @default.
- W4296385773 created "2022-09-20" @default.
- W4296385773 creator A5054932432 @default.
- W4296385773 creator A5089175796 @default.
- W4296385773 date "2022-09-01" @default.
- W4296385773 modified "2023-10-18" @default.
- W4296385773 title "P3.04: Apraglutide Treatment Reduces Chemotherapy-Induced Gastrointestinal (GI) Damage in Mice and Preserves Cellular Integrity During Chemotherapy" @default.
- W4296385773 doi "https://doi.org/10.1097/01.tp.0000888248.98846.e1" @default.
- W4296385773 hasPublicationYear "2022" @default.
- W4296385773 type Work @default.
- W4296385773 citedByCount "1" @default.
- W4296385773 countsByYear W42963857732023 @default.
- W4296385773 crossrefType "journal-article" @default.
- W4296385773 hasAuthorship W4296385773A5054932432 @default.
- W4296385773 hasAuthorship W4296385773A5089175796 @default.
- W4296385773 hasBestOaLocation W42963857731 @default.
- W4296385773 hasConcept C126322002 @default.
- W4296385773 hasConcept C2776694085 @default.
- W4296385773 hasConcept C2778041864 @default.
- W4296385773 hasConcept C2778496288 @default.
- W4296385773 hasConcept C2778684742 @default.
- W4296385773 hasConcept C2779384505 @default.
- W4296385773 hasConcept C71924100 @default.
- W4296385773 hasConcept C90924648 @default.
- W4296385773 hasConcept C98274493 @default.
- W4296385773 hasConceptScore W4296385773C126322002 @default.
- W4296385773 hasConceptScore W4296385773C2776694085 @default.
- W4296385773 hasConceptScore W4296385773C2778041864 @default.
- W4296385773 hasConceptScore W4296385773C2778496288 @default.
- W4296385773 hasConceptScore W4296385773C2778684742 @default.
- W4296385773 hasConceptScore W4296385773C2779384505 @default.
- W4296385773 hasConceptScore W4296385773C71924100 @default.
- W4296385773 hasConceptScore W4296385773C90924648 @default.
- W4296385773 hasConceptScore W4296385773C98274493 @default.
- W4296385773 hasIssue "9S" @default.
- W4296385773 hasLocation W42963857731 @default.
- W4296385773 hasLocation W42963857732 @default.
- W4296385773 hasOpenAccess W4296385773 @default.
- W4296385773 hasPrimaryLocation W42963857731 @default.
- W4296385773 hasRelatedWork W1999938278 @default.
- W4296385773 hasRelatedWork W2046693401 @default.
- W4296385773 hasRelatedWork W2163996738 @default.
- W4296385773 hasRelatedWork W2299494654 @default.
- W4296385773 hasRelatedWork W2388037374 @default.
- W4296385773 hasRelatedWork W2589677112 @default.
- W4296385773 hasRelatedWork W2949760313 @default.
- W4296385773 hasRelatedWork W320195515 @default.
- W4296385773 hasRelatedWork W4386116444 @default.
- W4296385773 hasRelatedWork W2398290995 @default.
- W4296385773 hasVolume "106" @default.
- W4296385773 isParatext "false" @default.
- W4296385773 isRetracted "false" @default.
- W4296385773 workType "article" @default.